Dapagliflozin & Sitagliptin fixed dose combination in India T2D: 5 Point Clinicians May Like to Know-Dr K Baraneedharan

The burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective intervention is essential to ensure durable glycemic control and prevent long-term complications. In the Indian population, marked by higher insulin resistance, reduced beta-cell function, abdominal obesity, and clustering of cardiovascular risk factors, the case for early combination therapy is particularly important. This article reviews five recent data points relevant to clinicians considering the Dapagliflozin (SGLT2 inhibitor) and Sitagliptin (DPP-4 inhibitor) combination in T2DM management.[1]

1. Dapagliflozin & Sitagliptin Combination – Experienced Beta-Cell Independent complementary citing agents coming together: The dapagliflozin (SGLT2i) & sitagliptin (DPP4i) combination targets complementary and mechanistically distinct pathways involved in glucose regulation (Figure 1). Sitagliptin enhances incretin-mediated, glucose-dependent insulin secretion by DPP-4, thereby increasing endogenous incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Dapagliflozin lowers plasma glucose by selectively inhibiting SGLT2 in the proximal renal tubule, promoting urinary glucose excretion independent of insulin secretion and without the hypo-glycaemia or weight gain associated with conventional therapies.[2]

Figure 1. Complementary mechanisms of action of SGLT2 inhibitors and DPP-4 inhibitors in glucose regulation. Adapted from: Chadha M, Das AK, Deb P, et al. Expert Opinion: Optimum Clinical Approach to Combination-Use of SGLT2i + DPP4i in the Indian Diabetes Setting. Diabetes Therapy. 2022;13:1097–1114. Abbreviations: SGLT2i -Sodium-glucose co-transporter-2 inhibitor, DPP-4i – Dipeptidyl peptidase-4 inhibitor, GLP-1 – Glucagon-like peptide-1, GIP – Glucose-dependent insulinotropic polypeptide, SBP – Systolic blood pressure

2. Dapagliflozin & Sitagliptin Combination in Indian T2D: Evidence of Gluco-Cardio-Metabolic Benefits:

An Indian multi-center real-world study (N=328; 111 centers) evaluated the dapagliflozin–sitagliptin fixed-dose combination (FDC) in patients with type 2 diabetes mellitus (T2DM), many of whom had cardiometabolic comorbidities, including hypertension (71.65%) and dyslipidemia (42.38%). Treatment with the FDC significantly improved glycemic parameters, with HbA1c decreasing by 1.05% (from 8.36% to 7.31%, p<0.0001) over 12 weeks. Fasting plasma glucose declined by 41.70 mg/dL (from 165.52 to 123.82 mg/dL, p<0.0001), while postprandial blood glucose decreased by 71.91 mg/dL (from 242.15 to 170.24 mg/dL, p<0.0001) during follow-up. In addition to glycemic control, the combination demonstrated favorable cardiometabolic effects, with systolic blood pressure decreasing by 14.61 mmHg (from 147.00 to 132.40 mmHg) and diastolic blood pressure by 7.80 mmHg (from 90.32 to 82.52 mmHg). LDL-cholesterol also declined by 18.14 mg/dL (from 121.40 to 103.20 mg/dL, p<0.0001). These findings provide evidence supporting the glycemic and cardiometabolic benefits of the dapagliflozin–sitagliptin FDC in a comorbidity-burdened T2DM population.[3]

3. Dapagliflozin's Cardiorenal Benefits Maintained When Combined with a DPP-4 Inhibitor: A trial-level meta-analysis of cardiovascular outcome trials (up to 37,687 participants) found that the cardiorenal benefits of SGLT2 inhibitors — including 3-point MACE (N=32,418), cardiovascular death or heart failure hospitalization (N=37,687), heart failure hospitalization alone (N=27,545), cardiovascular death (N=34,565), and renal outcomes (N=25,406) were statistically similar regardless of background DPP-4 inhibitor therapy (P heterogeneity = 0.71, 0.07, 0.87, 0.72, and 0.25, respectively).[4] For clinicians prescribing the dapagliflozin–sitagliptin combination, this provides reassurance that dapagliflozin's established cardiorenal profile, demonstrated in DECLARE-TIMI 58, DAPA-HF, and DAPA-CKD is not attenuated by the addition of sitagliptin.[5] The TECOS trial has also confirmed the cardiovascular safety of sitagliptin, demonstrating no increase in major adverse cardiovascular events or hospitalization for heart failure when added to standard care in patients with T2D and established CVD.[6]

4. Real-World Indian Clinical Utilization Data Affirm Dapagliflozin & Sitagliptin Combination Adoption Across Diverse T2D Patient Profiles: A recently published multicenter cross-sectional study across 100 Indian clinics analyzed records of 873 T2DM patients prescribed the sitagliptin 100 mg + dapagliflozin 10 mg FDC (mean age 55.26 ± 11.46 years; diabetes duration 7.02 ± 5.86 years). About 36.8% were treatment-naïve, while 62.8% were switched from prior oral therapy due to inadequate glycemic control or comorbidities. Obesity (44.9%), cardiovascular disease (44.8%), and dyslipidemia (33.6%) were prevalent comorbidities, with concomitant antihypertensives (47.8%) and lipid-lowering/antiplatelet agents (32.3%) commonly co-prescribed. These prescribing patterns indicate that Indian clinicians are deploying the dapagliflozin–sitagliptin FDC across a broad cardiometabolic risk spectrum.[1]

5. Dapagliflozin and Sitagliptin Combination: Where Does Combination Therapy Sit in Latest Guidelines?

The updated February 2026 NICE NG28 guideline highlighted that SGLT2 inhibitors are now recommended as first-line therapy for newly diagnosed T2DM, and when eGFR declines below 45 mL/min/1.73 m², the guideline advises continuing the SGLT2 inhibitor for cardiorenal protection while adding a DPP-4 inhibitor to maintain glycemic control.[7] The ADA Standards of Care 2026 recommends considering combination therapy as initial treatment to shorten time to glycemic goal attainment, and advises consideration of SGLT2 inhibitors for patients with established or high-risk atherosclerotic cardiovascular disease, heart failure (with reduced or preserved ejection fraction), and for comprehensive cardiorenal risk reduction, irrespective of HbA1c. DPP-4 inhibitors are recognized as weight-neutral add-on agents. [8]

Taken together, these findings highlight the clinical relevance of the dapagliflozin sitagliptin FDC in the management of T2DM, particularly in the Indian population marked by needs for beta-cell preservation, and addressing a cluster of cardiovascular risk factors to mitigate the risk of diabetes related complications. Early combination therapy targeting complementary pathways may help ensure durable glycemic control and support use of the dapagliflozin sitagliptin FDC across a broad cardiometabolic risk spectrum in routine Indian T2DM care continuum.

Abbreviations: ADA, American Diabetes Association; CVD, cardiovascular disease; DAPA-CKD, Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease; DAPA-HF, Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure; DBP, diastolic blood pressure; DECLARE-TIMI 58, Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; FDC, fixed-dose combination; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide-1; HbA1c, glycated haemoglobin; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular events; NICE, National Institute for Health and Care Excellence; NG28, NICE Guideline 28; PPBG, postprandial blood glucose; SBP, systolic blood pressure; SGLT2, sodium-glucose cotransporter-2; SIDAXA, Safety, Clinical Utilization, and Effectiveness of Sitagliptin and Dapagliflozin Combination Therapy in the Treatment of Type 2 Diabetes for Extra Glycaemic Advantages; T2DM, type 2 diabetes mellitus.